Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab plus albumin-bound paclitaxel for relapsed or refractory extranodal NK/T-cell lymphoma (nasal type)
ChiCTR2100043615Phase 2Recruiting
- Sponsor
- Sichuan Cancer Hospital
- Start
- May 2021
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab and paclitaxel in Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL), sponsored by Sichuan Cancer Hospital. Primary endpoint: Objective response rate. Started May 2021; status: recruiting.
02
Drugs
tislelizumabpaclitaxel
03
Conditions
Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL)
Beyond the preview
Go deeper on ChiCTR2100043615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100043615.